AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
Nov 3, 2021
31637_dirs_2021-11-03_f0d234e6-a0c0-4050-9653-c2da14658095.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-11-01
Reporting Person: Watts Ryan J. (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-11-01 | Common Stock | S | 1659 | $48.61 | Disposed | 2138375 | Indirect |
| 2021-11-01 | Common Stock | S | 16674 | $49.87 | Disposed | 2121701 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 151691 | Direct |
Footnotes
F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $48.20 to $49.19 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $49.27 to $50.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5: Includes 151,691 restricted stock units.